Entera Bio (ENTX) Enterprise Value (2017 - 2026)

Entera Bio (ENTX) has reported Enterprise Value for 10 consecutive years, with -$4.1 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value rose 67.1% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (up 67.1% YoY) and the FY2025 annual result came in at -$14.9 million, down 71.86% from the prior year.
• Enterprise Value improved to -$4.1 million in Q1 2026 per ENTX's latest filing, from -$14.9 million in the prior quarter.
• Over the last five years, Enterprise Value for ENTX reached as high as -$4.1 million in Q1 2026 and fell as low as -$20.1 million in Q1 2022.
• A 5-year average of -$11.0 million and a median of -$10.7 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2025 — Enterprise Value slumped 71.86% — and 2026, when it soared 67.1%.
• Year by year, Enterprise Value stood at -$12.3 million in 2022, then gained by 10.48% to -$11.0 million in 2023, then advanced by 21.41% to -$8.7 million in 2024, then sank by 71.86% to -$14.9 million in 2025, then jumped by 72.2% to -$4.1 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$4.1 million, -$14.9 million, and -$8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.